AR072041A1 - Piridil-n-(1,3,4) -tiadiazol-2-il-benceno sulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos - Google Patents

Piridil-n-(1,3,4) -tiadiazol-2-il-benceno sulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos

Info

Publication number
AR072041A1
AR072041A1 ARP080105715A ARP080105715A AR072041A1 AR 072041 A1 AR072041 A1 AR 072041A1 AR P080105715 A ARP080105715 A AR P080105715A AR P080105715 A ARP080105715 A AR P080105715A AR 072041 A1 AR072041 A1 AR 072041A1
Authority
AR
Argentina
Prior art keywords
alkylene
alkyl
cycloalkyl
trisubstituted
mono
Prior art date
Application number
ARP080105715A
Other languages
English (en)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR072041A1 publication Critical patent/AR072041A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Se refiere a N-[1,3,4]-tiadiazol-2-il-bencensulfonamidas c¡clicas y a sus sales fisiologicamente aceptables y derivados fisiologicamente funcionales que muestran actividad agonista de PPARdelta o PPARdelta y PPARgamma. Los compuestos son adecuados para el tratamiento y/o prevencion de trastornos de metabolismo de  cidos grasos y trastornos de utilizacion de la glucosa, as¡ como de trastornos en los que est  implicada la resistencia a la insulina y la desmielinizacion y otros trastornos neurodegenerativos del sistema nervioso central y periferico. Reivindicacion 1: Compuestos de la formula (1) donde R1 es alquilo C1-6, alquileno C0-6-cicloalquilo C3-6, alquileno C0-6-O-alquilo C1-6, alquileno C0-6-O-cicloalquilo C3-6, alquileno C0-6-arilo C6-14, alquileno C0-6-heteroarilo C5-15, en donde alquilo, alquileno, arilo, heteroarilo y cicloalquilo pueden estar no sustituidos o pueden estar mono-, di- o trisustituidos con F, CI, Br, alquilo C1-6, O-alquilo C1-6, CF3, OCF3, CN, CO-alquilo C1-6, COO-alquilo C1-6, CON-alquileno C0-6-H-alquileno C0-6-H, S(O)m-alquilo C1-6; R2, R3 son, de modo independiente, H, halogeno, alquilo C1-6, alquileno C0-4-O-alquileno C0-4-H, CN, COO-alquilo C1-6, CON-alquileno C0-6-H-alquileno C0-6-H, S(O)m-alquilo C1-6, en donde alquilo y alquileno son no sustituidos o mono-, di- o trisustituidos con F; R4, R5, R6 y R7 son, de modo independiente, H, alquilo C1-6, alquileno C0-6-cicloalquilo C3-6, alquileno C0-6-arilo C6-14, alquileno C0-6-heteroarilo C5-15, alquileno C0-6-heterocicloalquilo C3-15, alquileno C0-6-heterocicloalquenilo C3-15, en donde alquilo, alquileno y cicloalquilo no son sustituidos o son mono-, di- o trisustituidos con halogeno, alquilo C1-6, alquileno C0-6-O-alquileno C0-6-H, CF3, OCF3, CN, CO-alquilo C1-6, COO-alquilo C1-6, CON-alquileno C0-6- H-alquileno C0-6-H, S(O)m-alquilo C1-6, y en donde arilo, cicloalquilo, heterocicloalquilo, heterocicloalquenilo y heteroarilo no son sustituidos o son mono-, di- o trisustituidos con halogeno, CF3, alquilo C1-6 y alquileno C0-4-O-alquileno C0-4-H y en donde al menos un par de R4 y R5, R6 y R7, R5 y R6 junto con los  tomos de C a los que est n conectados, o R6 junto con el  tomo de C orto del anillo arom tico, forman un cicloalquilo C3-9, un heterocicloalquilo C3-9 o un heterocicloalquenilo C3-9, en donde cicloalquilo, heterocicloalquilo y heterocicloalquenilo no son sustituidos o son mono-, di- o trisustituidos con halogeno, CF3, alquilo C1-6 y alquileno C0-4-alquileno C0-4-H; m es 0, 1, 2; en todas sus formas estereoisomericas, formas enantiomericas y mezclas en cualquier relacion, y sus sales fisiologicamente aceptables y formas tautomericas.
ARP080105715A 2007-12-26 2008-12-23 Piridil-n-(1,3,4) -tiadiazol-2-il-benceno sulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos AR072041A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07291626 2007-12-26

Publications (1)

Publication Number Publication Date
AR072041A1 true AR072041A1 (es) 2010-08-04

Family

ID=39356534

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105715A AR072041A1 (es) 2007-12-26 2008-12-23 Piridil-n-(1,3,4) -tiadiazol-2-il-benceno sulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos

Country Status (14)

Country Link
US (1) US8344004B2 (es)
EP (1) EP2240474B1 (es)
JP (1) JP2011507914A (es)
KR (1) KR20100101165A (es)
CN (1) CN101910162A (es)
AR (1) AR072041A1 (es)
AT (1) ATE549332T1 (es)
AU (1) AU2008340756A1 (es)
BR (1) BRPI0821915A2 (es)
CA (1) CA2710441A1 (es)
IL (1) IL206531A0 (es)
MX (1) MX2010006647A (es)
TW (1) TW200940536A (es)
WO (1) WO2009080223A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2667545A1 (en) * 2006-10-25 2008-05-02 Neurosearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011140190A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Tetrazolones as inhibitors of fatty acid synthase
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TWI754702B (zh) * 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類
WO2019023579A1 (en) * 2017-07-27 2019-01-31 The Mclean Hospital Corporation METHODS AND COMPOSITIONS RELATING TO THE TREATMENT OF PATHOLOGIES MEDIATED BY NURR1 AND PPARY
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
PL3986890T3 (pl) 2019-06-18 2024-03-11 Pfizer Inc. Pochodne benzizoksazolosulfonamidu

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3522638A1 (de) * 1985-06-25 1987-01-08 Diamalt Ag Neue somatostatin-derivate
AU2381397A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
CN100447139C (zh) 2003-07-08 2008-12-31 诺瓦提斯公司 苯磺酰氨基化合物和含有这些化合物的药物组合物
CA2624726A1 (en) 2005-10-06 2007-04-12 Sanofi-Aventis 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
ATE487706T1 (de) 2005-10-06 2010-11-15 Sanofi Aventis Cyclische n-ä1,3,4ü-thiadiazol-2-yl- benzsulfonamide, verfahren zu deren herstellung und deren verwendung als arzneimittel

Also Published As

Publication number Publication date
CN101910162A (zh) 2010-12-08
AU2008340756A1 (en) 2009-07-02
MX2010006647A (es) 2010-08-17
ATE549332T1 (de) 2012-03-15
IL206531A0 (en) 2010-12-30
US20110224263A1 (en) 2011-09-15
KR20100101165A (ko) 2010-09-16
TW200940536A (en) 2009-10-01
BRPI0821915A2 (pt) 2015-06-16
WO2009080223A1 (en) 2009-07-02
US8344004B2 (en) 2013-01-01
EP2240474B1 (en) 2012-03-14
EP2240474A1 (en) 2010-10-20
JP2011507914A (ja) 2011-03-10
CA2710441A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
AR072041A1 (es) Piridil-n-(1,3,4) -tiadiazol-2-il-benceno sulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos
AR072013A1 (es) Sulfonamidas n-heterociclicas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparacion y su uso como sustancias farmaceuticas
AR064299A1 (es) Derivados de sulfonil-fenil-2h- [1,2,4] oxadiazol-5-ona procesos para su preparacion y su uso como agentes farmaceuticos
ECSP088323A (es) Derivados de fenil-[1,2,4]-oxadiazol-5-ona con grupo fenilo, procedimientos para su preparación y su uso como productos farmacéuticos
ECSP088322A (es) Derivados de fenil-1,2,4-oxadiazolona, procesos para su preparación y su uso como compuestos farmacéuticos
AR072014A1 (es) Sulfonamidas con grupo de cabeza de heterociclo y oxadiazolona, procesos para su preparacion y su uso como sustancias farmaceuticas
UY31873A (es) Pirrolidin sulfonamidas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparación y su uso como sustancias farmacéuticas
ECSP19028657A (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer
BR112015025140A2 (pt) 2-fenilimidazo[1,2-a]pirimidinas como agentes de imagem
PE20090049A1 (es) Derivados de piridopirimidina como moduladores de la actividad de pde 4
UY34239A (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
ECSP066892A (es) Derivados de oxadiazolona como agonistas de ppar delta
AR071925A1 (es) Malonamidas como antagonistas de orexina
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
ECSP066669A (es) Indoles, 1h-indazoles, 1,2-benzisoxazoles, y 1,2-benzisotiazoles, y preparación y usos de los mismos
CU24177B1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
UY33485A (es) Derivados de acido(2-ariloxiacetilamino)fenilpropionico, procedimientos para su preparacion y uso de los mismos como medicamentos.
AR057145A1 (es) N-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas con actividad antagonista de receptores ppardelta o ppardelta y ppargamma
CO6260069A2 (es) Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa
AR056121A1 (es) 4-oxi-n- [1.3.4 -tiadiazol-2-il-bencenosulfonamidas, procesos para su preparacion y su uso como productos farmaceuticos
ECSP16090804A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
DOP2018000083A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
NI201600161A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
AR056563A1 (es) [1,3,4]-tiadiazol-2-il-amidas biciclicas del acido aril-sulfonico, procesos para su preparacion y su uso como productos farmaceuticos

Legal Events

Date Code Title Description
FB Suspension of granting procedure